Haemonetics周一表示，美国食品和药物管理局批准了其用于封闭微创心脏和血管手术过程中形成的动脉开口的装置。该公司股票在延长交易时段上涨约1.2%。
Haemonetics said on Monday the US Food and Drug Administration approved its device designed to seal arterial openings created during minimally invasive heart and vascular procedures.
该装置名为PerQseal Elite，采用完全可吸收的补丁，随时间溶解，不会在体内留下永久性植入物。Haemonetics在2026年1月收购爱尔兰Vivasure Medical时获得了该技术。FDA的批准覆盖了该装置与结构性心脏和血管内手术中常用的大尺寸导入鞘的使用。Haemonetics表示，医生可以在手术过程中确认出血是否停止，而不会失去导丝通道。
公司还表示，将在本月晚些时候的导管心血管治疗大会上展示更多临床数据。Haemonetics销售采血、血液管理和介入医疗产品，包括用于心血管手术的血管闭合技术。
Shares of the medical technology company rose about 1.2% in extended trading. The device, PerQseal Elite, uses a fully absorbable patch that dissolves over time and does not leave a permanent implant in the body Haemonetics obtained the technology as part of its January 2026 acquisition of Ireland-based Vivasure Medical FDA's approval covers use of the device with large access sheaths commonly used in structural heart and endovascular procedures Haemonetics said physicians can confirm if bleeding has stopped without losing guidewire access during the procedure The company also said it will present additional clinical data at the Transcatheter Cardiovascular Therapeutics conference later this month Haemonetics sells blood collection, blood management and interventional medical products, including vascular closure technologies used in cardiovascular procedures